A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors

Exclusion Criteria15

• History of ≥2 primary malignancies within 5 years prior to informed consent.
• Received anti-tumor treatment within 4 weeks or within the 5 half-lives of the previous treatment (whichever is shorter) before dosing.
• Medication of other unmarketed investigational drugs or therapies within 4 weeks before dosing.
• Undergone major organ surgery (excluding biopsy) or significant trauma within 4 weeks before dosing or requiring elective surgery during the study.
• Vaccinated with attenuated live vaccines within 4 weeks before dosing.
• Treated with with systemic corticosteroids within 14 days before dosing.
• Central nervous system metastasis.
• Uncontrolled third-space effusion.
• Serious cardiovascular or cerebrovascular diseases.
• Severe lung disease affecting pulmonary function.
• Active infection requiring systemic therapy.
• Known hypersensitivity or delayed allergic reaction to the investigational product or its components.
• Drug abuse or other medical/psychiatric condition that may interfere with study participation or results.
• Known alcohol or drug dependence.
• Pregnant or breastfeeding women, or individuals planning to conceive.